# Double Staining Immunohistochemistry and Digital Pathology: Moving Towards Standardization of the Proliferative Index Evaluation in Meningiomas

**Authors:** Viscardo Paolo Fabbri, Giuseppe Broggi, Giovanna Attolini, Vincenzo L’Imperio, Fabio Pagni, Angela Guerriero, Stefano Marletta, Francesco Fiorentino, Stefania Caramaschi, Claudia Malagoli, Albino Eccher, Rosario Caltabiano

PMC · DOI: 10.3390/jpm16030148 · 2026-03-04

## TL;DR

This study shows that double staining and digital pathology can improve the accuracy of evaluating the proliferation index in meningiomas, helping standardize tumor grading.

## Contribution

The study introduces a standardized method using double staining immunohistochemistry and digital pathology for meningioma proliferation index evaluation.

## Key findings

- Ki-67 expression varied by meningioma grade, with digital image analysis showing high agreement with manual assessments.
- Double staining immunohistochemistry improved accuracy in evaluating diagnostic and proliferative markers in tumor samples.

## Abstract

Background: Although Ki-67 is not included among the grading criteria in the current WHO Classification of Tumours of the Central Nervous System (CNS), it provides valuable, albeit limited, prognostic information. Immunohistochemistry for Ki-67 can reveal uneven proliferation patterns and assist in the assessment of mitotic counts. Several studies indicate that meningiomas with a proliferation index > 4% show recurrence rates comparable to CNS WHO grade 2 (atypical) tumors, while tumors with an index > 20% are associated with mortality rates similar to CNS WHO grade 3 (anaplastic) meningiomas. Issues related to Ki-67 assessment include interobserver variability, the use of different cut-off values among pathologists, and the presence of a complex inflammatory tumour microenvironment, which may lead to an overestimation of the proliferative index (PI). Methods: In this study, we describe how Double Staining Immunohistochemistry (dIHC) with EMA/Ki-67 better highlights neoplastic meningothelial cells compared with single-stain evaluation. Furthermore, the application of Digital Pathology provides quantitative digital data that allow a more accurate assessment of proliferation. Results: Ki-67 expression varied by grade, with digital image analysis (dIHC) showing high agreement with manual assessments. dIHC improved accuracy in evaluating diagnostic and proliferative markers within tumor samples. Conclusions: dIHC combined with DP can support and standardize the evaluation of the proliferative index in meningiomas in routine diagnostic practice.

## Linked entities

- **Proteins:** Mki67 (antigen identified by monoclonal antibody Ki 67), ETFA (electron transfer flavoprotein subunit alpha)

## Full-text entities

- **Genes:** ANPEP (alanyl aminopeptidase, membrane) [NCBI Gene 290] {aka AP-M, AP-N, APN, CD13, GP150, LAP1}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, BAP1 (BRCA1 associated deubiquitinase 1) [NCBI Gene 8314] {aka HUCEP-13, KURIS, TPDS1, UBM2, UCHL2, UVM2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, SMARCE1 (SWI/SNF related BAF chromatin remodeling complex subunit E1) [NCBI Gene 6605] {aka BAF57, CSS5}, SMO (smoothened, frizzled class receptor) [NCBI Gene 6608] {aka CRJS, FZD11, Gx, PHLS, SMOH}, SSTR2 (somatostatin receptor 2) [NCBI Gene 6752] {aka SST2}, NF2 (NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor) [NCBI Gene 4771] {aka ACN, BANF, SCH, SWNV, merlin-1}, KLF4 (KLF transcription factor 4) [NCBI Gene 9314] {aka EZF, GKLF}, TRAF7 (TNF receptor associated factor 7) [NCBI Gene 84231] {aka CAFDADD, RFWD1, RNF119}, SRPRA (SRP receptor subunit alpha) [NCBI Gene 6734] {aka DP, SRPR, Sralpha}
- **Diseases:** aRT (MESH:D001169), Chordoid meningiomas (MESH:D008579), H&amp;E (MESH:D016751), gliomas (MESH:D005910), injury to (MESH:D014947), 3 tumours (MESH:D009369), PM (MESH:D010554), grade 1, 2, and 3 meningiomas (MESH:D008224), breast cancer (MESH:D001943), necrosis (MESH:D009336), anaplastic (MESH:D002277), CNS neoplasms (MESH:D016543), central nervous system lesions (MESH:D002493), inflammatory (MESH:D007249), invasion (MESH:D009361)
- **Chemicals:** formalin (MESH:D005557), DP (MESH:D004176), Fast Red (MESH:C005215), CC1 (-), paraffin (MESH:D010232), 3,3'-diaminobenzidine (MESH:D015100), hematoxylin (MESH:D006416)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027794/full.md

---
Source: https://tomesphere.com/paper/PMC13027794